Rinat Efrima - Im Cannabis Chief Israel
| IMCC Stock | USD 3.99 0.30 8.13% |
Insider
Rinat Efrima is Chief Israel of Im Cannabis Corp
| Age | 47 |
| Address | Kibbutz Glil Yam, Tel Aviv, Israel, 4690500 |
| Phone | 972 5 44331111 |
| Web | https://imcannabis.com |
Im Cannabis Management Efficiency
The company has return on total asset (ROA) of (0.1718) % which means that it has lost $0.1718 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1201) %, meaning that it created substantial loss on money invested by shareholders. Im Cannabis' management efficiency ratios could be used to measure how well Im Cannabis manages its routine affairs as well as how well it operates its assets and liabilities. As of December 2, 2024, Return On Tangible Assets is expected to decline to -0.3. In addition to that, Return On Capital Employed is expected to decline to -0.8. At present, Im Cannabis' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 25.5 M, whereas Total Assets are forecasted to decline to about 28 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Quinn Deveraux | Inhibrx | N/A | |
| Janice Hitchcock | Acumen Pharmaceuticals | N/A | |
| Eric Lindquist | Celcuity LLC | N/A | |
| W Vernon | Nuvation Bio | 65 | |
| David MD | Nuvation Bio | 54 | |
| Kerry Wentworth | Nuvation Bio | 51 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Sergey Yurasov | Nuvation Bio | 51 | |
| Liean MS | Acumen Pharmaceuticals | N/A | |
| Mark Lappe | Inhibrx | 57 | |
| Lei Sun | Connect Biopharma Holdings | 60 | |
| Gregory Flesher | Eledon Pharmaceuticals | 54 | |
| David Hanley | Nuvation Bio | 54 | |
| Kim Blickenstaff | Nuvation Bio | 68 | |
| Steven Chan | Connect Biopharma Holdings | 52 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| James JD | Eliem Therapeutics | 58 | |
| Vicky Hahne | Celcuity LLC | 58 | |
| Michelle Doig | Nuvation Bio | 46 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Oleg Nodelman | Nuvation Bio | 44 | |
Management Performance
| Return On Equity | -1.12 | ||||
| Return On Asset | -0.17 |
Im Cannabis Corp Leadership Team
Elected by the shareholders, the Im Cannabis' board of directors comprises two types of representatives: Im Cannabis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IMCC. The board's role is to monitor Im Cannabis' management team and ensure that shareholders' interests are well served. Im Cannabis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Im Cannabis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shai Shemesh, Chief Officer | ||
| Advocate Nissimov, General Counsel | ||
| Anna Taranko, Director Relations | ||
| Michael Ruscetta, Chief Corp | ||
| Richard Balla, Chief Adjupharm | ||
| Rinat Efrima, Chief Israel | ||
| Howard CFA, Chief MYM | ||
| Advocate Harrosh, Chief Officer | ||
| Uri Birenberg, Chief Officer | ||
| MSc MBA, Executive Chairman | ||
| Oren Shuster, CEO Director |
IMCC Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Im Cannabis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.12 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.28) % | ||||
| Operating Margin | (0.20) % | ||||
| Current Valuation | 21.92 M | ||||
| Shares Outstanding | 3.09 M | ||||
| Shares Owned By Insiders | 46.99 % | ||||
| Shares Owned By Institutions | 6.12 % | ||||
| Number Of Shares Shorted | 17.52 K | ||||
| Price To Book | 2.90 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Im Cannabis Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Im Cannabis' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Im Cannabis Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Im Cannabis Corp Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Im Cannabis Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Im Cannabis. If investors know IMCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Im Cannabis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.13) | Revenue Per Share 22.335 | Quarterly Revenue Growth 0.117 | Return On Assets (0.17) | Return On Equity (1.12) |
The market value of Im Cannabis Corp is measured differently than its book value, which is the value of IMCC that is recorded on the company's balance sheet. Investors also form their own opinion of Im Cannabis' value that differs from its market value or its book value, called intrinsic value, which is Im Cannabis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Im Cannabis' market value can be influenced by many factors that don't directly affect Im Cannabis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Im Cannabis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Im Cannabis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Im Cannabis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.